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ABSTRACT 
 
The physiological function of human uncoupling protein-3 is still unknown. Uncoupling protein-
3 is increased during fasting and high-fat feeding. In these situations the availability of fatty 
acids to the mitochondria exceeds the capacity to metabolize fatty acids, suggesting a role for 
uncoupling protein-3 in handling of non-metabolizable fatty acids. To test the hypothesis that 
uncoupling protein-3 acts as a mitochondrial exporter of non-metabolizable fatty acids from the 
mitochondrial matrix, we gave human subjects Etomoxir (which blocks mitochondrial entry of 
fatty acids) or placebo in a cross-over design during a 36-h stay in a respiration chamber. 
Etomoxir inhibited 24-h fat oxidation and fat oxidation during exercise by ~1419%. 
Surprisingly, uncoupling protein-3 content in human vastus lateralis muscle was markedly up-
regulated within 36 h of Etomoxir administration. Up-regulation of uncoupling protein-3 was 
accompanied by lowered fasting blood glucose and increased translocation of glucose 
transporter-4. These data support the hypothesis that the physiological function of uncoupling 
protein-3 is to facilitate the outward transport of non-metabolizable fatty acids from the 
mitochondrial matrix and thus prevents mitochondria from the potential deleterious effects of 
high fatty acid levels. In addition our data show that up-regulation of uncoupling protein-3 can 
be beneficial in the treatment of type 2 diabetes. 
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he human uncoupling protein-3 (UCP3) is a recently identified member of the uncoupling 
protein family, which is expressed primarily in skeletal muscle. The physiological function 
of UCP3 is still unresolved (1, 2). Due to its homology with the brown adipose tissue-
specific uncoupling protein-1 (UCP1), UCP3 was suggested to be involved in human energy 
turnover and obesity (3, 4). However, mice lacking UCP3 have a normal metabolic rate and body 
weight (5, 6), and fasting, an energy preserving condition, rapidly up-regulates the expression of 
UCP3 (7), contradicting a role for UCP3 in the regulation of energy turnover. Rather, UCP3 
protein content is consistently up-regulated in situations in which fatty acid delivery to skeletal 
muscle exceeds the muscle's fat oxidative capacity, such as fasting, acute exercise, and high-fat 
feeding (79). On the other hand, a reduction of UCP3 protein content is observed in situations 
in which fat oxidative capacity is improved, such as after endurance training (10) and after 
weight reduction (11). Finally, we showed that UCP3 protein content is highest in type 2b 
muscle fibers, which are characterized by a low capacity to oxidize fatty acids and therefore are 
unable to metabolize all cytosolic fatty acids (12). Together with the finding that UCP3 can 
transport fatty acid anions (13), these results suggest that UCP3 might be involved in the 
mitochondrial transport of non-metabolizable fatty acids (14).  
 
The majority of the fatty acids in the cytoplasm are converted to their esterified form (fatty acyl-
CoA) by the enzyme fatty acyl-CoA synthetase and then transported into the mitochondria by the 
enzyme carnitine-palmitoyl-transferase-1 (CPT1). Only in the esterified form, fatty acids can 
undergo ß-oxidation. Fatty acids that cannot be esterified accumulate in the cytosol and these 
non-esterified fatty acids can enter the mitochondria by a so-called flip-flop mechanism (15). 
Due to the higher pH inside the mitochondrial matrix, part of these non-esterified fatty acids will 
be deprotonated, resulting in fatty acid anions. Because a fatty acid anion can neither be 
metabolized inside the matrix nor cross the inner mitochondrial membrane (16), they are trapped 
inside the matrix, where they can have deleterious effects on mitochondrial function, for example 
due to lipid peroxidation. To test whether UCP3 is indeed involved in the transport of non-
metabolizable fatty acid anions, we created a situation in which the concentration of non-
metabolizable fatty acids will increase, by reducing the fat oxidative capacity and hypothesized 
that UCP3 would be increased in such a situation. Therefore, we gave healthy volunteers 
Etomoxir, an inhibitor of CPT1 and thus of the of the transport of fatty acids into the 
mitochondria, and measured fat oxidation and UCP3 protein content in skeletal muscle.  
 
METHODS 
 
Subjects 
 
Ten healthy, lean young men (BMI = 21.8 ± 0.3 kg/m2; age = 25.6 ± 1.7 y, % type 1 fibers: 44.1 
± 3.5%) participated in the study. The Medical Ethics Committee of the University of Maastricht 
approved the study, and subjects gave their written informed consent.  
 
Experimental design 
 
Each subject underwent two treatments in randomized order. Every treatment lasted for 5 days. 
To create a situation in which fat oxidative capacity was maximally utilized, subjects were 
provided with high-fat diets for consumption at home during three days. On the evening of the 
third day subjects entered the respiration chamber for a 36 h stay (20.0008.00 h) to allow the 
continuous determination of fatty acid oxidation. During the stay in the respiration chamber, 
subjects again consumed a high-fat diet and they were given oral dosages of either Etomoxir 
(day 3: 75 mg in the evening; day 4: 150 mg in the morning and afternoon; and 75 mg in the 
evening, day 5: 150 mg in the morning) or placebo (same time schedule with the same amount of 
capsules, but not containing any drug) under supervision in randomized order. This resulted in a 
total Etomoxir dose of 600 mg over the 36 h in the respiration chamber. A fasting blood sample 
was taken on the mornings of day 4 and day 5. On day 5 at 08.00 h subjects left the respiration 
chamber and a muscle biopsy was taken. After this, subjects exercised on a cycle ergometer for 2 
h at 50% of their predetermined maximal performance. During the exercise test, blood samples 
were taken every 30 min (at t = 30, 60, 90 and 120 minutes) and indirect calorimetry was 
performed every half-hour. 
 
Diets 
 
Metabolizable energy intake and macronutrient composition of the diet was calculated by using 
the Dutch food composition table (17). The high-fat diet consisted of 60 energy % fat, 30 energy 
% carbohydrate, and 10 energy % protein. Milk fat was excluded from the high-fat diet because 
of its high content in medium-chain fatty acids. This ensured that mainly long-chain fatty acids 
contributed to the fat content in the high-fat diet.  
 
Indirect calorimetry 
 
Oxygen consumption and carbon dioxide production were measured in a respiration chamber, as 
previously described (18). The respiration chamber is a 14 m3 room and is ventilated with fresh 
air at a rate of 7080 l/min. The ventilation rate is measured with a dry gas meter (Schlumberger, 
type G6, The Netherlands). The concentrations of oxygen and carbon dioxide are measured by 
using a paramagnetic O2 analyzer (Hartmann & Braun, type Magnos G6, Germany) and an 
infrared CO2 analyzer (Hartmann & Braun, type Uras 3G, Germany). Ingoing air was analyzed 
every 15 minutes and outgoing air once every 5 minutes. During exercise oxygen consumption 
and carbon dioxide production were measured using open circuit spirometry (Oxycon-ß 
Mijnhard, The Netherlands). 
 
In the respiration chamber, subjects followed an activity protocol consisting of fixed times for 
breakfast, lunch, and dinner, sedentary activities and bench-stepping exercise (three times daily 
for 15 min). Throughout the daytime, no sleeping or other exercise was allowed during the stay 
in the respiration chamber. 
 
We measured 24-h substrate oxidation from 8.00 h on day 4 to 8.00 h on day 5. Substrate 
oxidation during sleep was measured from 00.30 h to 7.00 h. Carbohydrate, fat and protein 
oxidation were calculated by using O2-consumption, CO2-production and urinary nitrogen losses 
with the equations of Brouwer (19). 
 
Urinary nitrogen excretion 
 
During the stay in the respiration chamber, urine was collected in two batches, one from 20.00 h 
to 8.00 h and one over the subsequent 24-h interval. Subjects were requested to empty their 
bladders at 8.00 h. The urine produced was included in the urine sample of the previous batch. 
Samples were collected in containers with 10 mL H2SO4 to prevent nitrogen loss through 
evaporation; volume and nitrogen concentration were measured, the latter by using a nitrogen 
analyzer (Carlo-Erba, type CN-O-Rapid). 
 
Blood analyses  
 
Venous blood samples (10 mL) were obtained in EDTA-tubes and immediately centrifuged at 
high speed for 10 min. Plasma was frozen in liquid nitrogen and stored at 80oC until analysis of 
glucose (Hexokinase method, Roche, Basel, Switzerland), free fatty acids (FFA)(Wako NEFA C 
test kit, Wako chemicals, Neuss, Germany), and beta-hydroxybutyrate (BHB) (20). 
 
Muscle biopsy and analysis 
 
Muscle biopsies were taken from the mid-thigh region from M. vastus lateralis according to the 
technique of Bergström. For Western-blot detection of UCP3 an affinity-purified rabbit 
polyclonal antibody (code: 1331, kindly provided from L.J. Slieker, Eli Lilly and Co., 
Indianapolis, IN) prepared against a 20 aa-peptide (human sequence aa 147166), was used, as 
previously described (11). Fiber typing was performed by indirect immunofluoresence by using a 
mouse monoclonal IgM antibody against slow myosin (MHC1, A4.840, Developmental 
Hybridoma Bank, Iowa City, IA). Subcellular localization of GLUT4 was performed by indirect 
immunofluoresence by using an affinity-purified antibody (21). All samples were treated 
identical with regard to dilution of the antibody, incubation time, and camera settings (exposure 
time and gain). Quantitative image analysis to determine the green fluorescent GLUT4 signal in 
sarcoplasm and subsarcolemmal region was performed by using LUCIA G/F image analysis 
software. 
 
Statistical analysis 
 
Data are presented as mean ± SE. Differences between Etomoxir and placebo were analyzed pair-
wise with Student's t-tests. A two-factor repeated measures ANOVA with interactions was used 
to detect treatment * time interactions in selected variables. When significant differences were 
found, a Bonferroni adjusted post hoc test was used to determine the exact location of the 
difference. Pearsons correlation coefficients were calculated to determine the relationship 
between selected variables. Outcomes were regarded as statistically significant if P<0.05. 
 
RESULTS 
 
Substrate metabolism 
 
Twenty-four hour fat oxidation was reduced significantly, by ~14% after Etomoxir 
administration (158 ± 6 gram per 24 h with placebo vs. 136 ± 5 gram per 24 h with Etomoxir, 
P<0.05, Fig. 1A). As a result, 24-h carbohydrate oxidation was higher after Etomoxir (214 ± 16 
gram per 24 h with placebo vs. 252 ± 12 gram per 24 h with Etomoxir, P<0.05). Twenty-four 
hour protein oxidation was not affected by Etomoxir (65 ± 5 gram per 24 h with placebo vs. 65 ± 
4 gram per 24 h with Etomoxir, NS). 
 
During the first night in the respiration chamber, only a few hours after administration of the first 
dosage of Etomoxir or placebo, fat oxidation tended to be lower after Etomoxir administration, 
but the difference did not reach statistical significance (142 ± 7 gram per 24 h with placebo vs. 
130 ± 6 gram per 24 h with Etomoxir, P=0.12, Fig. 1B). However, fat oxidation was reduced 
significantly by ~19% during the second night in the respiration chamber (139 ± 5 gram per 24 h 
with placebo vs. 113 ± 4 gram per 24 h with Etomoxir, P<0.005, Fig. 1B). Again, the inhibition 
of fat oxidation resulted in an increase in carbohydrate oxidation, which was only significant 
during the second night (first night: 39 ± 10 gram per 24 h with placebo vs. 51 ± 7 gram per 24 h 
with Etomoxir, NS; second night: 37 ± 9 gram per 24 h with placebo vs. 70 ± 7 gram per 24h 
with Etomoxir, P=0.05). 
 
During the 2 h of exercise, fat oxidation gradually increased (P<0.05), and there was a 
significant time*treatment effect (P<0.05), indicating that this increase was attenuated after 
Etomoxir administration (Fig. 1C). Post-hoc testing revealed that the Etomoxir-induced 
reduction in fat oxidation reached significance at t = 90 (667 ± 43 mg/min with placebo vs. 602 ± 
42 mg/min with Etomoxir, P<0.05) and at t = 120 (730 ± 45 mg/min with placebo vs. 641 ± 49 
mg/min with Etomoxir, P<0.05). Carbohydrate oxidation during exercise was not affected by 
Etomoxir. 
 
Blood substrates 
 
Plasma FFA levels at rest were not significantly affected by Etomoxir administration (487 ± 76 
µmol/l after Etomoxir vs. 382 ± 44 µmol/ after placebo, NS). During exercise, FFA increased 
from 359 ± 55 µmol/l at t = 30 to 1002 ± 109 µmol/l at t = 120 with placebo, but this increase 
during exercise tended to be more pronounced after Etomoxir (380 ± 59 µmol/l at t = 30 to 1122 
± 130 µmol/l at t = 120 with Etomoxir, P=0.08). Fasting plasma glucose levels were 
significantly lower in the morning of day 5 (4.60 ± 0.14 mmol/l after Etomoxir vs. 4.84 ± 0.13 
mmol/ after placebo, P<0.01). During exercise, glucose levels decreased in both treatments, but 
the decrease was much more pronounced after Etomoxir (from 4.6 ± 0.1 mmol/l at t = 30 to 4.0 ± 
0.1 mmol/l at t = 120 with placebo and from 4.4 ± 0.2 mmol/l at t = 30 to 3.5 ± 0.1 mmol/l at t = 
120 with Etomoxir, P<0.05). Plasma beta-hydroxybutyrate (BHB) concentration both at rest and 
during exercise was not affected by Etomoxir.  
 
UCP3 protein content 
 
Etomoxir administration increased UCP3 protein content in all subjects, on average by ~67%, 
compared with placebo (72 ± 8 arbitrary units after Etomoxir vs. 43 ± 11 arbitrary units after 
placebo, P<0.0005, Fig. 2). The increase in UCP3 induced by Etomoxir was negatively 
correlated with the Etomoxir induced decrease in fat oxidation both during the first (r = -0.77, 
P<0.05) and second night (r = 0.77, P<0.05, Fig. 3) in the respiration chamber and with 24-h fat 
oxidation (r = 0.71, P<0.05). The Etomoxir-induced increase in UCP3 protein, correlated very 
strongly and negatively (r = 0.89, P<0.005) with the change in fasting BHB concentration 
between Etomoxir and placebo. There was no correlation between Etomoxir-induced increase in 
UCP3 protein and fiber type composition. 
 
GLUT 4 translocation 
 
To examine whether up-regulation of UCP3 following Etomoxir administration, as a secondary 
effect, promoted translocation of GLUT4 in human skeletal muscle, we visualized subcellular 
localization of GLUT4 by immunofluorescence. Quantitative image analysis of all fasting (pre-
exercise) samples revealed that the ratio of the intensity of the green fluorescent GLUT4 signal 
in sarcolemma: sarcoplasm was significantly higher after Etomoxir compared with placebo (1.18 
± 0.02 vs. 1.12 ± 0.02, P<0.05), indicating increased recruitment of GLUT4 to the cell surface 
(Representative pictures after placebo and after Etomoxir are shown in Fig. 4). There was no 
correlation between Etomoxir-induced increase in GLUT4 translocation and fiber type 
composition. 
 
DISCUSSION 
 
Soon after the discovery of human UCP3, indications were found that the primary physiological 
role of UCP3 is not the regulation of energy turnover, as would be predicted from its homology 
to UCP1. Thus, mice lacking UCP3 have a normal metabolic rate and body weight (5, 6), and 
fasting, an energy preserving condition, rapidly up-regulates the expression of UCP3 (7). Rather, 
several groups suggested a role for UCP3 in fatty acid handling (7, 22, 23, 24). Based on the 
finding that UCP3 content is high in situations in which fatty acid delivery to the muscle exceeds 
the oxidative capacity, we hypothesized that UCP3 functions as an outward transporter of non-
esterified fatty acid anions from the mitochondrial matrix, thereby protecting mitochondria 
against accumulation of non-esterified fatty acids that entered the mitochondrial matrix by flip-
flop across the mitochondrial inner membrane (14). In the present study, we used Etomoxir to 
inhibit CPT1, thereby reducing the capacity of fatty acids to enter the mitochondria in a form 
(fatty acyl-CoA) in which they are available for oxidation. We observed that 24-h fat oxidation 
was reduced by ~14 %. During the night, the contribution of fatty acids to total substrate 
oxidation increases and therefore fat oxidation was determined during each night separately. 
Already a few hours after the first dose of Etomoxir, during the first night in the respiration 
chamber, fat oxidation tended to be lower. During the second night, Etomoxir reduced fat 
oxidation by ~19%, illustrating a cumulative effect of repeated Etomoxir administration. It is 
well-documented that during moderate-intensity exercise both the relative contribution and the 
absolute rate of fatty acid oxidation are high (25). Again, Etomoxir could reduce fat oxidation in 
this situation. Together these data show that Etomoxir was effective in lowering fat oxidative 
capacity by ~1419%, indicating that Etomoxir reduced the entry of esterified fatty acids into the 
mitochondria. For comparison, the complete absence of acetyl-CoA carboxylase, which 
indirectly inhibits CPT1, increases fat oxidation by ~ 30% (26), indicating that a 1419% 
reduction in fat oxidation undeniably reflects an effective blockade of CPT1. Consequently, non-
esterified (non-metabolizable) fatty acids accumulate in the cytoplasm and the entry of these 
non-esterified fatty acids into the mitochondrial matrix by flip-flop is increased.  
 
Next, we examined whether this reduction in fat oxidative capacity would indeed lead to an 
increase in UCP3 protein content. Using Western blotting we found that Etomoxir administration 
increased UCP3 protein content in all subjects, on average by ~67%, compared with placebo. 
Because Etomoxir was not equally efficient in reducing fat oxidation in all subjects, we also 
examined whether the increase in UCP3 protein content after Etomoxir administration was 
related to the observed decrease in fat oxidation. We found that the increase in UCP3 induced by 
Etomoxir was negatively correlated with the Etomoxir induced decrease in fat oxidation, 
illustrating that the up-regulation of UCP3 after Etomoxir depends on the reduction of fat 
oxidative capacity.  
 
When the breakdown of lipids predominates and/or oxaloacetate availability is reduced, acetyl-
CoA is diverted to the formation of beta-hydroxybutyrate (BHB) in the liver. Blocking CPT1 
will therefore result in reduced BHB production. Because Etomoxir has equal affinity to inhibit 
CPT1 in liver and muscle, plasma BHB is an indirect indicator of the efficacy of CPT1-blockade 
in skeletal muscle. We observed that the change in fasting BHB concentration between Etomoxir 
and placebo correlated very strongly and negatively with the Etomoxir-induced increase in 
UCP3 protein, indicating that inhibition of entry of esterified fatty acids via CPT1 into the 
mitochondria is crucial for the increase in UCP3 content. 
 
The very pronounced and rapid increase of UCP3 protein content upon blocking CPT1 by 
Etomoxir in a situation where the entry of esterified (metabolizable) fatty acids into the 
mitochondria is reduced, supports our hypothesis that the physiological function of UCP3 is the 
outward transport of non-esterified fatty acid anions from the mitochondrial matrix. In the 
situation where CPT1 is blocked non-esterified (and thus non-metabolizable) fatty acids are 
likely to accumulate in the cytosol but can also enter the mitochondrial matrix by a so-called 
flip-flop mechanism (15), after which they will be deprotonated. UCP3 can protect mitochondria 
from these non-esterified fatty acids by providing outward transport of these fatty acid anions. 
This physiological function for UCP3 can also explain previous findings that UCP3 is up-
regulated in situations where fatty acid supply exceeds fat oxidation capacity (fasting, high-fat 
diet, T3 treatment, acute exercise), and that UCP3 is down-regulated in situations where fat 
oxidation capacity is improved (endurance training, weight reduction). The high expression of 
UCP3 in type IIB muscle fibers is also consistent with this hypothesis, especially because these 
muscle fibers, which are hardly able to oxidize fatty acids needs to be protected against 
mitochondrial non-esterified fatty acids accumulation. Outward transport of non-esterified fatty 
acid anions from the mitochondrial matrix by UCP3 has also been hypothesized by Himms-
Hagen et al. (27). However, it is of physiological relevance to note that they suggested that 
UCP3 exports fatty acid anions from the matrix, which are delivered by hydrolysis of fatty acyl-
CoA by mitochondrial thioesterases, when fatty acids are the principal substrate utilized. Clearly, 
the presently observed up-regulation of UCP3 upon inhibition of fat oxidation by CPT1 blockade 
is not in line with their hypothesis, though we cannot exclude that under certain conditions the 
fatty acid anions exported by UCP3 are derived from hydrolysis of fatty acyl-CoA. 
 
From the present study, we cannot deduce what the key regulatory signal is that induces the 
UCP3 gene after Etomoxir treatment. It has been shown before that plasma FFA are able to up-
regulate UCP3 mRNA expression (28), most likely because FFA are ligands for PPARs and the 
PPAR family has been shown to regulate UCP3 gene expression (29). However, UCP3 can also 
be increased when plasma FFA levels are unaltered. For example, the up-regulation of UCP3 
after long-term high-fat diet can not necessarily be attributed to changes in plasma FFA levels, 
since on the long-term high-fat diet consumption does not increase fasting plasma FFA levels 
(9). Similarly, the down-regulation of UCP3 with endurance training is not accompanied by a 
reduction in plasma FFA levels (10). In the present study, fasting levels of plasma FFA were not 
significantly increased after Etomoxir treatment. However, it cannot be ruled out the intracellular 
fatty acid or fatty acyl-CoA levels might have increased upon Etomoxir treatment, and that 
accumulation of these metabolites is responsible for the up-regulation of UCP3, as was 
suggested by Cabrero et al. (30). Alternatively, Etomoxir treatment has been shown to increase 
intramyocellular triglyceride pools in rats (31) and involvement of the muscular triglycerides 
pools in the up-regulation of UCP3 is well possible. However, in this context it is important to 
note that endurance-trained athletes have low levels of UCP3 (10) despite having increased 
intramuscular triglyceride levels (32). It is therefore more likely that accumulation of one or 
more metabolites involved in fatty acid metabolism (such as fatty acyl-CoA), due to an 
imbalance between fat availability and fat oxidative capacity rather than increased muscular lipid 
storage is involved in the regulation of UCP3. Further studies are needed to reveal the exact 
signals responsible for up-regulation of UCP3 in situations where the availability of fatty acids to 
the mitochondria exceeds fat oxidative capacity. 
 
As a consequence of the reduction in fat oxidative capacity, carbohydrate oxidation needs to 
increase to supply sufficient energy. Indeed, Etomoxir increased carbohydrate oxidation and 
reduced plasma glucose concentration, both at rest and during exercise. Regarding the latter it is 
interesting to note that mice overexpressing UCP3 are also characterized by lower plasma 
glucose levels and an improved glucose clearance rate (33). In L6 myotubes overexpression of 
UCP3 increases glucose uptake through an increased recruitment of glucose transporter-4 
(GLUT4) to the cell surface (34). Therefore, we examined whether up-regulation of UCP3 
following Etomoxir administration was accompanied by an increased translocation of GLUT4 in 
human skeletal muscle. Indeed, sarcolemmal staining was increased after Etomoxir, indicating 
increased recruitment of GLUT4 to the cell surface. However, whether the up-regulation of 
UCP3 and increased GLUT4 translocation are related events cannot be deduced from the present 
study. For example, it is not clear from the present study whether Etomoxir induced regulation of 
UCP3 and GLUT4 is similar in different fiber types, and therefore further studies are needed to 
examine the relationship between UCP3 and GLUT4 in single muscle fibers. 
 
In conclusion, we here present for the first time support for a novel physiological function of the 
human uncoupling protein 3 as an exporter of fatty acid anions. This physiological function of 
UCP3 can explain the majority of the findings on UCP3 regulation under different 
(physiological) conditions. Still, UCP3 could act as an uncoupling protein, since the outward 
transport of fatty acid anions actually decreases the proton gradient across the mitochondrial 
membrane, thereby uncoupling mitochondrial respiration, explaining the previously observed 
association of UCP3 with energy metabolism (33, 35). As a secondary effect, up-regulation of 
UCP3 was accompanied by GLUT4 translocation. Given that UCP3 protein content is decreased 
in type 2 diabetic subjects (36), UCP3 might be an important pharmaceutical target in the 
treatment of type 2 diabetes mellitus. 
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Fig. 1 
 
                          
   
              
Figure 1. Effect of Etomoxir. On  A) 24-h fat oxidation, B) fat oxidation measured during the night, and C) fat 
oxidation during exercise. Fat oxidation was calculated from oxygen consumption and carbon dioxide production, 
measured by indirect calorimetry. Open circles, placebo; solid circles, Etomoxir. *P<0.05 Compared with placebo. 
#P<0.05 compared with night 1. 
Fig. 2 
 
 
              
Figure 2. Effect of Etomoxir on UCP3 protein content (arbitrary units). *P<0.0005 compared with placebo. 
 
Fig. 3 
 
 
              
Figure 3. Increase in UCP3 protein content as a function of the degree of inhibition of fat oxidation by Etomoxir. 
 
Fig. 4 
 
 
              
Figure 4. Immunofluorescent staining of GLUT4 in cross sections of fasting m. vastus lateralis samples. 
After a) placebo and b) Etomoxir, showing increased sarcolemmal staining after Etomoxir. Bar represents 50 µm. 
 
